AOD 9604 is discussed heavily in weight loss peptide content and is not stocked by Healio. That fact belongs at the top of this article rather than buried in it, and the honest reason to still cover the compound is that it is searched often enough to deserve an accurate, unaffiliated explanation rather than silence.
This guide covers what AOD 9604 is, its origin as a fragment of a larger hormone, what research has actually examined, and where Healio’s stocked compounds sit as an alternative for anyone researching this space. Nothing here is guidance for personal use.
What is AOD 9604?
AOD 9604 is a synthetic peptide fragment derived from a region of human growth hormone associated with fat metabolism effects, developed with the specific aim of isolating that property from growth hormone’s other, broader effects on tissue growth generally.
The reasoning behind isolating a fragment rather than using the whole hormone is a pattern that recurs across several compounds in this catalog, covered in the KPV fragment logic: a larger molecule with several activities is harder to study cleanly than a fragment carrying just one of them.
What research has examined AOD 9604 for
Research on AOD 9604 has focused on the specific fat metabolism property it was designed to isolate, examined through preclinical study, in the general research pattern covered across growth hormone peptide research for compounds interacting with this broader signalling family.
The compound’s development history includes clinical trial work, which places it somewhat further along the evidence spectrum than the purely preclinical compounds in this catalog, though considerably short of achieving an approved formulation for any indication. The evidence tier framework goes through why partial clinical development sits meaningfully differently from either the fully approved compounds or the entirely preclinical ones.
Why AOD 9604 is not a general weight loss guarantee
The same caution that applies across this catalog’s metabolic compound coverage applies here, with the added note that this compound’s evidence base is considerably thinner than the fully approved metabolic peptides discussed elsewhere on this site.
A compound targeting one property of growth hormone’s broader activity is not automatically equivalent, in magnitude or reliability, to compounds like tirzepatide or semaglutide, which underwent full clinical development programs specifically targeting weight and metabolic outcomes as primary endpoints. The evidence-ranked weight loss overview sets out where those compounds sit by comparison.
Where AOD 9604 fits among growth hormone-related compounds
Placing it in the wider family it belongs to clarifies the comparison people are usually reaching for when they search this term.
Tesamorelin, the compound Healio does stock in the growth hormone secretagogue class, works by an entirely different mechanism, stimulating the pituitary’s own production through a GHRH analogue pathway, rather than by isolating a fragment of the hormone itself. The tesamorelin research lays out that mechanism and its own narrow, specific approval.
These are mechanistically distinct approaches to the same broad hormonal system, not interchangeable variations on a theme, and neither should be assumed to produce the other’s specific documented effects.
Why fragment compounds are attractive research targets generally
AOD 9604 belongs to a broader pattern worth understanding, since it recurs across this catalog with different parent hormones and different isolated fragments each time. A large signalling molecule with several distinct biological activities is a difficult research subject precisely because any observed effect could plausibly be arriving through several of those activities at once, making the specific mechanism hard to pin down. Isolating the sequence responsible for one particular activity, as researchers attempted with the growth hormone fragment behind AOD 9604, produces a cleaner research object with fewer confounding variables, even though it does not guarantee the isolated fragment retains the full potency or reliability of the activity it was extracted from. The KPV fragment logic covers the same design logic applied to a different parent hormone.
What Healio stocks as an alternative research direction
Stated plainly: Healio does not carry AOD 9604. Anyone researching the growth hormone and metabolic compound space more broadly can find tesamorelin, retatrutide, tirzepatide and semaglutide in the weight loss collection, each with its own distinct mechanism and evidence profile covered in its individual guide.
Sourcing standards apply to any supplier of AOD 9604
For anyone sourcing this compound elsewhere, the same verification standard covered throughout this catalog applies regardless of supplier: a batch-specific certificate of analysis from a named independent laboratory, purity by HPLC, identity by mass spectrometry, and a lot number matching the vial. The certificate of analysis walkthrough and supplier checklist cover what to demand before ordering from any source.
Where AOD 9604 came from
The compound has a more specific origin than most of this catalogue, and the origin explains both the interest and the disappointment.
Human growth hormone is a 191 amino acid protein with several distinct activities. Researchers at Monash University worked on the idea that its effect on fat metabolism could be separated from its other effects, and identified a fragment corresponding to the C-terminal region, residues 177 to 191, that appeared to retain the lipolytic activity.
AOD stands for anti-obesity drug, which tells you exactly what it was built for. The appeal was obvious: growth hormone’s fat-handling effects without the growth-promoting effects, the insulin resistance, or the tissue growth that makes GH administration problematic.
Metabolic Pharmaceuticals took it into clinical development. That is more than almost anything else in this catalogue can claim.
What the trials actually found
This is the part usually left out of pages selling the compound.
AOD 9604 reached human clinical trials for obesity, and the results did not support the hypothesis. The compound did not produce the weight reduction the preclinical work had suggested, and development for that indication did not continue to approval.
That is a meaningful finding rather than an absence of one. A great many compounds here have never been tested in humans, so nothing can be said either way. AOD 9604 was tested and the answer was disappointing, which is a different and more informative situation.
Later work explored other directions, including osteoarthritis and cartilage-related applications, which is a very different indication from the one it was designed for. That redirection is itself a signal about how the obesity results were received.
The compound also received a specific regulatory classification in some jurisdictions as a food ingredient rather than a therapeutic, which is not the same as approval for anything.
The mechanism, and why it looked promising
Understanding the proposed mechanism explains why the failure surprised people.
Growth hormone influences fat metabolism partly through effects on lipolysis, the breakdown of stored triglycerides, and on lipogenesis, their formation. The fragment hypothesis held that a short C-terminal region carried this activity independently of the receptor binding responsible for GH’s growth effects.
Animal work supported it. Rodent studies reported effects on fat metabolism without the glucose handling problems that accompany full growth hormone.
Why it did not translate is the open question. Possibilities include species differences in the relevant pathway, exposure levels that animal work reached and human dosing did not, or the fragment simply not doing in humans what it appeared to do in mice. Nobody has resolved it.
The wider category is in growth hormone peptides.
AOD 9604 compared to what does have metabolic evidence
| Compound | Mechanism | Human trial outcome |
|---|---|---|
| AOD 9604 | GH fragment, lipolysis | Did not meet obesity endpoints |
| Semaglutide | GLP-1 agonism | Approved |
| Tirzepatide | GLP-1 and GIP | Approved |
| Tesamorelin | GHRH analogue | Approved for visceral fat in a specific population |
The comparison is not flattering and it is the relevant context. The incretin compounds did what AOD 9604 was designed to do, through a completely different mechanism, and reached approval.
Those sit in the weight loss collection.
Why AOD 9604 is still sold and still searched
A compound that failed its trials remains one of the more marketed items in this space, which is worth examining rather than ignoring.
Part of it is that the mechanism story is genuinely appealing. Separating fat metabolism from growth effects is an elegant idea and easy to explain, and elegant ideas outlive the data that contradicts them.
Part of it is that failure is quiet. Approval generates coverage; discontinued development does not, so the preclinical enthusiasm remains searchable long after the trial results.
And part of it is that “did not meet its endpoints” is easy to omit. A page can describe the mechanism accurately, cite the animal work honestly, and simply not mention the human results.
Healio does not stock AOD 9604. This page exists because the compound is searched for, and describing it accurately is more useful than pretending the question does not come up.
What a negative trial result is worth knowing
There is a broader point here that applies well beyond this compound.
Absence of evidence and evidence of absence are different situations, and most of this catalogue sits in the first. BPC-157 has no human trials, so nothing is established either way. AOD 9604 has human trials that did not support the hypothesis, which is stronger information.
A reader deciding between compounds should weight those differently. An untested compound is an open question. A tested compound that did not perform is a closed one, unless later work reopens it.
That distinction rarely survives contact with product marketing, where both get described as promising.
AOD 9604: frequently asked questions
What is AOD 9604?
A synthetic peptide fragment derived from a region of human growth hormone associated with fat metabolism effects, developed to isolate that specific property from growth hormone’s broader activity.
Does Healio sell AOD 9604?
No. Healio’s growth hormone-related research compound is tesamorelin, which works through a different mechanism, stimulating endogenous growth hormone production rather than isolating a hormone fragment.
Is AOD 9604 approved for any indication?
No. It has undergone some clinical trial work, which places it further along the evidence spectrum than purely preclinical compounds, though it has not achieved an approved formulation for any indication.
Is AOD 9604 comparable to tirzepatide or semaglutide in evidence strength?
No. Those compounds underwent full clinical development programs targeting weight and metabolic outcomes directly as primary endpoints, giving them a substantially more mature evidence base than AOD 9604 currently has.
Does AOD 9604 work for fat loss?
Human clinical trials for obesity did not support the hypothesis, and development for that indication did not continue to approval. The preclinical animal work was more promising, which is why the compound retains a reputation the human data does not back.
Why is AOD 9604 still marketed?
The mechanism story is appealing and easy to explain, failed development generates no coverage, and “did not meet its endpoints” is easy to leave out of a page describing the animal research accurately.
Is AOD 9604 the same as growth hormone?
No. It is a fragment corresponding to residues 177 to 191 of the 191 amino acid protein, isolated on the hypothesis that the fat metabolism activity could be separated from the growth-promoting activity.
Does Healio sell AOD 9604?
No. This page exists because the compound is searched for, and an accurate account is more useful than pretending the question does not arise.
One closing thought that generalises beyond this compound. A tested compound that did not perform tells you more than an untested one, and the market treats both as equally promising. Learning to prefer the first kind of information is most of what separates a careful buyer from an enthusiastic one.
What did AOD 9604 get developed for?
Obesity. The name is short for anti-obesity drug, and the hypothesis was that a C-terminal fragment of growth hormone carried the fat metabolism activity without the growth-promoting effects.
Was it ever approved?
Not as a therapeutic. It received a food ingredient classification in some jurisdictions, which is a different thing from approval for an indication.
Covered honestly, not stocked here
AOD 9604 is a real, mechanistically specific compound with a genuine though limited evidence base, worth understanding accurately rather than either dismissing or overselling. Healio’s own metabolic and growth hormone offerings sit in the weight loss collection, every batch independently tested before it ships.
Related reading
- Tesamorelin Peptide, the growth hormone compound Healio does stock.
- Growth Hormone Peptides, the wider mechanistic family.
- Best Peptides for Weight Loss, the category ranked by evidence.
- How to Choose a Peptide Supplier, verification standards for any compound.